Abstract
Defective mitotic spindles or an impaired spindle–kinetochore interaction activates the spindle checkpoint. We have previously shown that BubR1 haplo-insufficiency results in enhanced genomic instability and tumorigenesis in mice. Here we report that BubR1 deficiency also leads to a compromised response to DNA damage. Following treatment with doxorubicin, BubR1+/− murine fibroblast cells (MEF) were defective in undergoing G2/M arrest. Thus, whereas in the presence of DNA damage BubR1+/+ MEF cells remained arrested in mitosis, BubR1+/− MEFs rapidly exited from mitosis and divided. The impaired mitotic arrest of BubR1+/− MEFs was associated with low levels of phospho-histone H2AX, p53, and p21 after DNA damage caused by treatment with both doxorubicin and ultraviolet light (UV). The impaired expression of p53 and p21 was also confirmed in human cell lines with BubR1 knockdown via RNA interference. Affinity pull-down coupled with mass spectrometry identified Poly(ADP-ribose) polymerase 1 (PARP-1) as one of the proteins interacting with BubR1. Reciprocal co-immunoprecipitation analysis confirmed the physical interaction between BubR1 and PARP-1. Our further study revealed that the ability of retaining intact PARP-1 or its cleavage product p89 was compromised in BubR1+/− MEFs upon treatment with doxorubicin or UV. Given that PARP-1 mediates DNA damage responses and regulates the activity of p53, our studies suggest that there exists a cross-talk between the spindle checkpoint and the DNA damage checkpoint and that BubR1 may play an important role in mediating the cross-talk.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Affar EB, Germain M, Winstall E, Vodenicharov M, Shah RG, Salvesen GS et al. (2001). J Biol Chem 276: 2935–2942.
Bashir T, Dorrello NV, Amador V, Guardavaccaro D, Pagano M . (2004). Nature 428: 190–193.
Bernal JA, Luna R, Espina A, Lazaro I, Ramos-Morales F, Romero F et al. (2002). Nat Genet 32: 306–311.
Bharadwaj R, Yu H . (2004). Oncogene 23: 2016–2027.
Bloom J, Amador V, Bartolini F, DeMartino G, Pagano M . (2003). Cell 115: 71–82.
Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD et al. (1998). Nature 392: 300–303.
Chang P, Jacobson MK, Mitchison TJ . (2004). Nature 432: 645–649.
Dai W, Wang Q, Liu T-Y, Swamy M, Fang Y-Q, Xie S-Q et al. (2004). Cancer Res 15: 440–445.
Hamid T, Kakar SS . (2003). Histol Histopathol 18: 245–251.
Hanks S, Coleman K, Reid S, Plaja A, Firth H, Fitzpatrick D et al. (2004). Nat Genet 36: 1159–1161.
Huber A, Bai P, de Murcia JM, de Murcia G . (2004). DNA Repair (Amsterdam) 3: 1103–1108.
Lengauer C . (2003). Science 300: 442–443.
Lengauer C, Kinzler KW, Vogelstein B . (1998). Nature 396: 643–649.
Lew DJ, Burke DJ . (2003). Annu Rev Genet 37: 251–282.
Li W, Lan Z, Wu H, Wu S, Meadows J, Chen J et al. (1999). Cell Growth Differ 10: 769–775.
Menissier dM, Ricoul M, Tartier L, Niedergang C, Huber A, Dantzer F et al. (2003). EMBO J 22: 2255–2263.
Mikhailov A, Cole RW, Rieder CL . (2002). Curr Biol 12: 1797–1806.
Nitta M, Kobayashi O, Honda S, Hirota T, Kuninaka S, Marumoto T et al. (2004). Oncogene 23: 6548–6558.
Ouyang B, Pan H, Lu L, Li J, Stambrook P, Li B et al. (1997). J Biol Chem 272: 28646–28651.
Pirrotta V . (2004). Cell 119: 735–736.
Rao CV, Yang M, Malisetty S, Liu T-Y, Fang Y-Q, Mahmood R et al. (2005). Proc Natl Acad Sci USA 102: 4365–4370.
Redon C, Pilch D, Rogakou E, Sedelnikova O, Newrock K, Bonner W . (2002). Curr Opin Genet Dev 12: 162–169.
Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S . (2004). Annu Rev Biochem 73: 39–85.
Saxena A, Saffery R, Wong LH, Kalitsis P, Choo KH . (2002). J Biol Chem 277: 26921–26926.
Smits VA, Klompmaker R, Arnaud L, Rijksen G, Nigg EA, Medema RH . (2000). Nat Cell Biol 2: 672–676.
Wang Q, Xie S, Chen J, Fukasawa K, Naik U, Traganos F et al. (2002). Mol Cell Biol 22: 3450–3459.
Wieler S, Gagne JP, Vaziri H, Poirier GG, Benchimol S . (2003). J Biol Chem 278: 18914–18921.
Xie S, Xie B, Lee MY, Dai W . (2005). Oncogene 24: 277–286.
Yang Y, Li CC, Weissman AM . (2004). Oncogene 23: 2096–2106.
Zhou BB, Elledge SJ . (2000). Nature 408: 433–439.
Zhou Y, Mehta KR, Choi AP, Scolavino S, Zhang X . (2003). J Biol Chem 278: 462–470.
Acknowledgements
We thank Xuan Huang for her assistance in working with phospho-H2AX antibody. We are also grateful to Lisa Buerle for administrative assistance and to co-workers in the laboratory for various discussions. The work is supported in part by a grant from the National Institutes of Health (RO1-CA90658) to WD.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fang, Y., Liu, T., Wang, X. et al. BubR1 is involved in regulation of DNA damage responses. Oncogene 25, 3598–3605 (2006). https://doi.org/10.1038/sj.onc.1209392
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1209392
Keywords
This article is cited by
-
Aneuploidy and chromosomal instability in cancer: a jackpot to chaos
Cell Division (2015)
-
Increased expression of BubR1 protects against aneuploidy and cancer and extends healthy lifespan
Nature Cell Biology (2013)
-
212Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint
British Journal of Cancer (2013)
-
Predictive and prognostic values of Tau and BubR1 protein in prostate cancer and their relationship to the Gleason score
Medical Oncology (2013)
-
Mitotic chromosomal instability and cancer: mouse modelling of the human disease
Nature Reviews Cancer (2010)